Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: sargramostim
Drug: busulfan
Drug: etoposide
Drug: fludarabine phosphate
Drug: prednisone
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-03-17

Last Posted Date: 2013-08-14

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 5

Registration Number: NCT00304018

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Phase 3

Completed

Conditions: Stage III Adrenal Cortical Carcinoma AJCC v7
Stage I Adrenal Cortical Carcinoma AJCC v7
Stage II Adrenal Cortical Carcinoma AJCC v7
Stage IV Adrenal Cortical Carcinoma AJCC v7

Interventions: Procedure: Conventional Surgery
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Biological: Filgrastim
Drug: Mitotane
Biological: Pegfilgrastim

First Posted Date: 2006-03-17

Last Posted Date: 2024-02-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 78

Registration Number: NCT00304070

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada

and more 88 locations

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma

Not Applicable

Conditions: Neuroblastoma

First Posted Date: 2006-02-07

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 120

Registration Number: NCT00287950

Locations: 🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇮🇪
Our Lady's Hospital for Sick Children, Dublin, Ireland

and more 18 locations

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Phase 2

Terminated

Conditions: Unusual Cancers of Childhood
Chronic Myeloproliferative Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: busulfan
Drug: carmustine
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methotrexate
Drug: cytarabine
Drug: mycophenolate mofetil
Drug: etoposide
Drug: methylprednisolone
Drug: tacrolimus
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-01-25

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 200

Registration Number: NCT00281879

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas

Phase 3

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: cisplatin
Drug: etoposide
Drug: ifosfamide
Drug: lomustine
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2006-01-18

Last Posted Date: 2013-12-19

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Target Recruit Count: 150

Registration Number: NCT00278278

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Etoposide in Treating Young Patients With Relapsed Ependymoma

Phase 2

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-01-18

Last Posted Date: 2013-08-07

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 14

Registration Number: NCT00278252

Locations: 🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2006-01-13

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00276731

Locations: 🇬🇧
Institute of Child Health at University of Bristol, Bristol, England, United Kingdom
🇬🇧
Royal London Hospital, London, England, United Kingdom
🇬🇧
Sir James Spence Institute of Child Health, Newcastle-Upon-Tyne, England, United Kingdom

and more 18 locations

Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors

Not Applicable

Conditions: Brain and Central Nervous System Tumors
Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2006-01-13

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 100

Registration Number: NCT00276718

Locations: 🇮🇪
Our Lady's Hospital for Sick Children, Dublin, Ireland
🇬🇧
Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom

and more 18 locations

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2006-01-13

Last Posted Date: 2016-09-26

Lead Sponsor: German CLL Study Group

Target Recruit Count: 30

Registration Number: NCT00276809

Locations: 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪
Universitatsklinikum Heidelberg, Heidelberg, Germany
🇩🇪
University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany

and more 9 locations

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: filgrastim
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2006-01-11

Last Posted Date: 2018-05-11

Lead Sponsor: German CLL Study Group

Target Recruit Count: 169

Registration Number: NCT00275015

Locations: 🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch, Berlin, Germany
🇩🇪
Internistische Praxis - Trier, Trier, Germany

and more 50 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy